Current opinion in allergy and clinical immunology · 2026
Botulinum toxin for allergic rhinitis: a systematic review and meta-analysis of its therapeutic potential.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wee Eric Tan Jin, Kueh Yee Cheng, Lazim Norhafiza Mat, Abdullah Baharudin
Аннотация
PURPOSE OF REVIEW: Botulinum toxin type A (BTX-A) is emerging as a promising intervention for refractory allergic rhinitis. This study evaluates its effectiveness in treating refractory allergic rhinitis.
RECENT FINDINGS: The primary outcome was total nasal symptom score (TNSS), while secondary outcomes included individual nasal symptom scores, quality of life (QOL), and adverse effects. Five trials involving 187 patients (mean age: 31.8 years) were included. BTX-A significantly improved TNSS at 4 weeks [SMD -2.07, 95% confidence interval (95% CI) -3.58 to -0.56; P < 0.001] and 12 weeks (SMD -2.42, 95% CI -4.22 to -0.62; P < 0.001). Neither comparison of BTX-A with triamcinolone injection nor oral cetirizine showed a significant difference in TNSS (SMD - 0.51, 95% CI -1.25 to 0.24; P = 0.18 and SMD 0.50, 95% CI -0.07 to 1.06; P = 0.08, respectively). In the BTX-A group, significant improvements were observed in rhinorrhea (SMD -2.18, 95% CI -3.74 to -0.62; P < 0.001), sneezing (SMD -1.88, 95% CI -2.60 to -1.15; P < 0.001), and itchiness (MD -1.57, 95% CI -2.45 to -0.69; P < 0.001) at 4 weeks, with these effects persisting up to 12 weeks. No serious adverse events occurred following BTX-A administration.
SUMMARY: BTX-A shows promise as an adjunctive therapy for refractory allergic rhinitis.
RECENT FINDINGS: The primary outcome was total nasal symptom score (TNSS), while secondary outcomes included individual nasal symptom scores, quality of life (QOL), and adverse effects. Five trials involving 187 patients (mean age: 31.8 years) were included. BTX-A significantly improved TNSS at 4 weeks [SMD -2.07, 95% confidence interval (95% CI) -3.58 to -0.56; P < 0.001] and 12 weeks (SMD -2.42, 95% CI -4.22 to -0.62; P < 0.001). Neither comparison of BTX-A with triamcinolone injection nor oral cetirizine showed a significant difference in TNSS (SMD - 0.51, 95% CI -1.25 to 0.24; P = 0.18 and SMD 0.50, 95% CI -0.07 to 1.06; P = 0.08, respectively). In the BTX-A group, significant improvements were observed in rhinorrhea (SMD -2.18, 95% CI -3.74 to -0.62; P < 0.001), sneezing (SMD -1.88, 95% CI -2.60 to -1.15; P < 0.001), and itchiness (MD -1.57, 95% CI -2.45 to -0.69; P < 0.001) at 4 weeks, with these effects persisting up to 12 weeks. No serious adverse events occurred following BTX-A administration.
SUMMARY: BTX-A shows promise as an adjunctive therapy for refractory allergic rhinitis.